Intravesical Atropine Compared to Oral Oxybutynin for Neurogenic Detrusor Overactivity: A Double-Blind, Randomized Crossover Trial

Journal of Urology

Volumn 177, Issue 1, 2007, Pages 208-213

  Fader, Mandy ^a,b   Glickman, Scott ^e,f   Haggar, Veronica ^b   Barton, Rachel ^d   Brooks, Rodney ^g   Malone Lee, James ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Continence and Skin Technology Group ^*  (United Kingdom)

^c Department of Medicine ^*  (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Vale of Aylesbury Primary Care Trust   (United Kingdom)

^f BARNET HOSPITAL   (United Kingdom)

^g Caulfield General Medical Centre   (Australia)

Author keywords

bladder; cholinergic antagonists; multiple sclerosis; urinary catheterization; urinary incontinence

Indexed keywords

ATROPINE; OXYBUTYNIN; PLACEBO;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DETRUSOR DYSSYNERGIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FECES INCONTINENCE; FEMALE; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MICTURITION DISORDER; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NIGHT SWEAT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH PAIN; THORAX PAIN; TREATMENT OUTCOME; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; ADULT; AGED; ATROPINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 33845312624     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.099     Document Type: Article

References (16)

1. rd International Consultation on Incontinence (2005), Health Publication, Plymouth 1128
2. Araki I., Matsui M., Ozawa K., Nishimura M., Kuno S., and Saida T. Relationship between urinary symptoms and disease-related parameters in multiple sclerosis. J Neurol 249 (2002) 1010
3. Kim H.Y., Goodman C., Omessi E., Rivera V., Kattan M.W., and Boone T.B. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 159 (1998) 972
4. Hay-Smith J., Herbison P., Ellis G., and Moore K. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 3 (2002)
5. Greenfield S.P., and Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol 146 (1991) 532
6. Enzelsberger H., Helmer H., and Kurz C. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomized trial. Br J Obstet Gynaecol 102 (1995) 929
7. Lehtoranta K., Tainio H., Lukkari-Lax E., Hakonen T., and Tammela T.L. Parmacokinetics, efficacy and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 36 (2002) 18
8. Ferrara P., D'Aleo C.M., Tarquini E., Salvatore S., and Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 87 (2001) 674
9. Glickman S., Tsokkos N., and Shah P.J.R. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. Paraplegia 33 (1995) 36
10. Deaney C., Glickman S., Gluck T., and Malone-Lee J.G. Intravesical atropine suppression of detrusor hyperreflexia in multiple sclerosis. J Neurol Neurosurg Psychiatry 65 (1998) 957
11. Enskat R., Deaney C.N., and Glickman S. Systemic effects of intravesical atropine sulphate. BJU Int 87 (2001) 613
12. rd International Consultation on Incontinence (2005), Health Publication, Plymouth
13. Kelleher C.J., Cardozo L.D., and Toozs-Hobson P.M. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol 7 (1995) 404
14. Malone-Lee J., Shaffu B., Anand C., and Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 165 (2001) 1452
15. Hills M., and Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 58 (2004) S703
16. Betts C.D., D'Mellow M.T., and Fowler C.J. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 56 (1993) 245